FML-S by AbbVie is clinical pharmacology corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. Approved for inflammatory conditions of the palpebral, bulbar conjunctiva, cornea and 8 more indications. First approved in 1989.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
FML-S is a fixed-dose ophthalmic suspension combining fluorometholone (a corticosteroid) and sulfacetamide sodium (an antimicrobial agent) for topical ocular use. It treats inflammatory conditions of the eye including conjunctivitis, uveitis, and corneal injury by suppressing inflammatory response and providing antimicrobial coverage. The corticosteroid inhibits edema, leukocyte migration, and fibroblast proliferation while the sulfacetamide provides bacteriostatic action against common ocular pathogens.
FML-S faces imminent loss of exclusivity with limited commercial investment, suggesting smaller team size and transition planning underway.
CLINICAL PHARMACOLOGY Corticosteroids suppress the inflammatory response to a variety of agents and they probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and…
Worked on FML-S at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
FML-S offers limited career momentum given its LOE trajectory and minimal open positions; roles are concentrated in defensive commercial and field operations rather than growth-oriented functions. Professionals assigned to this product should expect focus on market access, generic preparation, and cost management rather than expansion or innovation.